{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["26(12)"],"submitter":["Mitra D"],"pubmed_abstract":["Triple-negative breast cancer (TNBC) is the most elusive subtype of breast cancer that encounters treatment dilemmas owing to the paucity of druggable targets. We found hyperactivation of c-MET and ephrin type-A receptor 2 (EphA2) in patients treated with 5FU driven chemotherapy which correlated with lower disease-free survival. However, silencing of both these genes resulted in a marked decrease in the invasive, migratory, and tumorigenic potential of TNBC cells, indicating that a dual target strategy is actionable. Lupeol is a phytochemical, with potent anticancer efficacy and minimal side effects in preclinical studies. A synergistic strategy with 5FU and Lupeol elicited promising anticancer responses <i>in vitro</i>, <i>in vivo</i>, and in patient-derived <i>ex vivo</i> tumor culture models. This synergistic regimen is effective, even in the presence of HGF, which mechanistically orchestrates the activation of c-MET and EphA2. These data lay the foundation for the clinical validation of this combination therapy for TNBC patients."],"journal":["iScience"],"pagination":["108395"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10692664"],"repository":["biostudies-literature"],"pubmed_title":["Lupeol synergizes with 5-fluorouracil to combat c-MET/EphA2 mediated chemoresistance in triple negative breast cancer."],"pmcid":["PMC10692664"],"pubmed_authors":["Banerjee S","Nath P","Murmu N","Das G","Saha D","Mustafi SM","Mukherjee R","Majumder B","Mitra D","Alam N","Majumder A"],"additional_accession":[]},"is_claimable":false,"name":"Lupeol synergizes with 5-fluorouracil to combat c-MET/EphA2 mediated chemoresistance in triple negative breast cancer.","description":"Triple-negative breast cancer (TNBC) is the most elusive subtype of breast cancer that encounters treatment dilemmas owing to the paucity of druggable targets. We found hyperactivation of c-MET and ephrin type-A receptor 2 (EphA2) in patients treated with 5FU driven chemotherapy which correlated with lower disease-free survival. However, silencing of both these genes resulted in a marked decrease in the invasive, migratory, and tumorigenic potential of TNBC cells, indicating that a dual target strategy is actionable. Lupeol is a phytochemical, with potent anticancer efficacy and minimal side effects in preclinical studies. A synergistic strategy with 5FU and Lupeol elicited promising anticancer responses <i>in vitro</i>, <i>in vivo</i>, and in patient-derived <i>ex vivo</i> tumor culture models. This synergistic regimen is effective, even in the presence of HGF, which mechanistically orchestrates the activation of c-MET and EphA2. These data lay the foundation for the clinical validation of this combination therapy for TNBC patients.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-25T17:27:27.809Z","creation":"2025-04-25T17:27:27.809Z"},"accession":"S-EPMC10692664","cross_references":{"pubmed":["38047085"],"doi":["10.1016/j.isci.2023.108395"]}}